No abstract

No abstract

Hyperglycemia and insulin resistance resulted from uncontrolled diabetes mellitus (DM) had has been consistently associated with poor clinical outcome in patient with ischemic stroke. Hence, early diagnosis of DM, efficient glycemic control, and prevention of its complications, together using credible therapeutic approaches, are essential to avoid the stroke complications and minimize its financial burden. Candidate strategies used to control glycaemia failed to show an efficacy in stroke patients. Glucagon like peptide-1 (GLP-1) receptor agonists are novel antidiabetic agents with a proved neuroprotection effect. Herewith, we review the concept of GLP-1 use as a neuroprotective approach against DM-associated stroke.